Illumina, Inc. reported $4.49B of revenue over the trailing twelve months, +4.9% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $4.49B (to Q2 2026). Net income: $825M, trailing twelve months to Q2 2026. Free cash flow: $931M, trailing twelve months to Q2 2026. Operating margin: 20%, trailing twelve months to Q2 2026.

ILMNIllumina, Inc.

Healthcare

$278.10+171% 1Y

$278.10

$91.0052 weeks$293.84

ILMN as reported

Illumina, Inc. reported $4.49B of revenue over the trailing twelve months, +4.9% on the year before. 11 reported series are charted on this page, each one as filed.

$4.49B

Revenue, trailing twelve months · to Q2 2026 · +4.9% against the twelve months before

Net income: $825M
Net income · −34% year on year · trailing twelve months to Q2 2026
Free cash flow: $931M
Free cash flow · −9.7% year on year · trailing twelve months to Q2 2026
Operating margin: 20%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for ILMN, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$4.49B	+4.9%	Q2 2026
Net income	$825M	−34%	Q2 2026
EPS	$5.36	−32%	Q2 2026
Gross margin	66%	n/a	Q2 2026
Operating margin	20%	n/a	Q2 2026
Net margin	18%	n/a	Q2 2026
ROE	30%	n/a	Q2 2026
ROA	12%	n/a	Q2 2026
ROIC	34%	n/a	Q2 2026
Free cash flow	$931M	−9.7%	Q2 2026
P/E	51.9	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.